{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:02:32Z","timestamp":1783393352633,"version":"3.54.6"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients diagnosed with malignant tumors exhibit a markedly elevated risk of venous thromboembolism (VTE), which has a negative impact on their prognosis. Currently, there is no reliable predictive model specifically for thrombosis risk in lymphoma patients. This study aims to develop and validate a machine learning model leveraging real-world data, offering a dependable risk assessment tool for the early identification of VTE in lymphoma patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 605 hospitalized patients with lymphoma between January 2019 and June 2024. Candidate predictors included demographic characteristics, comorbidities and medical history, tumor-related factors, treatment-related factors, and laboratory parameters. The primary endpoint was the occurrence of VTE within 6\u00a0months after hospitalization for confirmed lymphoma. Model development incorporated three imputation methods, three sampling strategies, three feature selection approaches, and nine machine learning algorithms. Predictive performance was compared across all models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Combining different imputation, sampling, and feature selection strategies yielded 27 datasets, which were trained across nine algorithms to generate 243 models. The optimal model\u2014Simp-SMOTE_rf_GBM, constructed using random forest imputation, SMOTE oversampling, and gradient boosting machine\u2014achieved the highest predictive performance (AUC = 0.954). SHAP-based model interpretation identified nine key predictors ranked by importance: anticoagulant use, D-dimer, lactate dehydrogenase, central venous catheterization, carcinoembryonic antigen (CEA), Eastern Cooperative Oncology Group (ECOG) score, serum total protein (TP), total cholesterol (TC), and infectious disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study established and validated a machine learning model for predicting VTE risk in lymphoma patients, with the optimal model demonstrating excellent discriminatory ability (AUC = 0.954). The model provides evidence to guide the timing and strategy of anticoagulation, supporting early VTE screening and risk stratification in clinical practice. Its implementation has important implications for improving patient outcomes and advancing public health.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1691271","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:15:59Z","timestamp":1760415359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A study on a real-world data-based VTE risk prediction model for lymphoma patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Changli","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1160\/TH17-02-0116","article-title":"Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry","volume":"117","author":"Alatri","year":"2017","journal-title":"Thromb. Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ajh.24466","article-title":"Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients","volume":"91","author":"Antic","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1002\/cam4.4280","article-title":"Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma","volume":"10","author":"Bastos-Oreiro","year":"2021","journal-title":"Cancer Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3389\/fimmu.2019.02569","article-title":"Understanding infection-induced thrombosis: lessons learned from animal models","volume":"10","author":"Beristain-Covarrubias","year":"2019","journal-title":"Front. Immunol. 10"},{"key":"B6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2020005112","article-title":"Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era","volume":"137","author":"Bobillo","year":"2022","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1365-2141.1998.00732.x","article-title":"Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies","volume":"101","author":"Boraks","year":"1998","journal-title":"Br. J. Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events","volume":"115","author":"Caruso","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e038551","DOI":"10.1136\/bmjopen-2020-038551","article-title":"Impact of infection in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: insight from a multicentre observational cohort from China","volume":"10","author":"Chen","year":"2020","journal-title":"BMJ Open 10"},{"key":"B13","doi-asserted-by":"publisher","first-page":"901887","DOI":"10.3389\/fphar.2022.901887","article-title":"Characteristics and predictors of venous thromboembolism among lymphoma patients undergoing chemotherapy: a cohort study in China","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1111\/jth.12192","article-title":"Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis","volume":"11","author":"den Exter","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.25837","article-title":"Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models","volume":"95","author":"Dharmavaram","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3324\/haematol.2016.147405","article-title":"Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism","volume":"101","author":"Gran","year":"2016","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3760\/cma.j.issn.1672-7088.2018.11.011","article-title":"Relationship between PICC catheter-related thrombosis and coagulation index changes in cancer patients","volume":"34","author":"Guan","year":"2018","journal-title":"Chin. J. Pract. Nurs."},{"key":"B19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1445-5994.2002.00171.x","article-title":"Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis","volume":"32","author":"Heaton","year":"2002","journal-title":"Intern Med. J."},{"key":"B20","article-title":"\u201cCarcinoembryonic Antigen,\u201d in","author":"Kankanala","year":"2025","journal-title":"StatPearls"},{"key":"B21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"Kekre","year":"2019","journal-title":"Blood Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5732\/cjc.013.10120","article-title":"Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer","volume":"32","author":"Khan","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clml.2020.02.021","article-title":"The incidence of venous thromboembolism and impact on survival in hodgkin lymphoma","volume":"20","author":"Kirkizlar","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B24","doi-asserted-by":"publisher","first-page":"106537","DOI":"10.1016\/j.leukres.2021.106537","article-title":"Venous thromboembolic events in T-cell lymphoma patients: incidence, risk factors and clinical features","volume":"103","author":"Lan","year":"2021","journal-title":"Leuk. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4143\/crt.2014.266","article-title":"Cross-sectional study of patients with diffuse large B-Cell lymphoma: assessing the effect of host status, tumor burden, and inflammatory activity on venous thromboembolism","volume":"48","author":"Lim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1074\/jbc.M112.404301","article-title":"Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones","volume":"288","author":"Longstaff","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"B28","volume-title":"The epidemiological characteristics report of malignant lymphoma: analysis of 2,027 cases in a single institution","author":"Meng","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/sj.bjc.6602504","article-title":"Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis","volume":"92","author":"Mohren","year":"2005","journal-title":"Br. J. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.thromres.2018.03.016","article-title":"Incidence and risk factor of deep venous thrombosis in patients undergoing craniotomy for brain tumors: a Japanese single-center, retrospective study","volume":"165","author":"Nakano","year":"2018","journal-title":"Thromb. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3760\/cma.j.cn112152-20220511-00329","article-title":"Lymphoma expert committee of national cancer quality control center. Quality control index for standardized diagnosis and treatment of lymphoma in China (2022 edition)","volume":"44","year":"2025","journal-title":"Chin. J. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.thromres.2012.03.019","article-title":"Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population","volume":"130","author":"Park","year":"2012","journal-title":"Thromb. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-021-03791-x","article-title":"Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma","volume":"154","author":"Saito","year":"2021","journal-title":"J. Neurooncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s11239-024-02977-0","article-title":"Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma","volume":"57","author":"S\u00e1nchez Prieto","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","article-title":"Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma","volume":"143","author":"Sanfilippo","year":"2016","journal-title":"Thromb. Res."},{"key":"B36","first-page":"2022","article-title":"Research progress on risk factors and prediction models of venous thromboembolism in lymphoma","volume":"44","author":"Shang","year":"2023","journal-title":"Int. J. Laboratory Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B39","volume-title":"Clinical features and risk factors in patients with lymphomacomplicated with venous thromboembolism","author":"Wan","year":"2024"},{"key":"B40","first-page":"1071","article-title":"Analysis of risk factors for central venous catheter-related thrombosis in malignant tumor patients and construction of a risk prediction model","volume":"16","author":"Wang","year":"2023","journal-title":"Chin. J. New Clin. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3760\/cma.j.cn115355-20200221-00065","article-title":"Establishment risk Predict. nomogram model Up. Extrem. venous thrombosis Assoc. Peripher. venous inserted central catheter cancer patients","volume":"32","author":"Yang","year":"2020","journal-title":"Cancer Res. Clin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/1078155219851540","article-title":"The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: a 9-year single-center experience","volume":"26","author":"Y\u0131ld\u0131z","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B43","first-page":"47","article-title":"Prediction risk of upper limb venous thrombosis after PICC catheterization in cancer patients using decision tree model","volume":"41","author":"Ying L","year":"2024","journal-title":"Hosp. Manag. Forum"},{"key":"B44","first-page":"835","article-title":"Analysis of disease perception status and influencing factors in patients with malignant lymphoma","volume":"40","author":"Ying X. H","year":"2024","journal-title":"Mod. Med. Health"},{"key":"B45","volume-title":"Establishment and validation of a risk prediction model for venous thromboembolism in lymphoma patients","author":"Zhang","year":"2025"},{"key":"B46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1378\/chest.13-2379","article-title":"Prevalence and associations of VTE in patients with newly diagnosed lung cancer","volume":"146","author":"Zhang","year":"2014","journal-title":"Chest"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:16:03Z","timestamp":1760415363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1691271"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1691271","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"1691271"}}